306 related articles for article (PubMed ID: 24195946)
1. Using exome data to identify malignant hyperthermia susceptibility mutations.
Gonsalves SG; Ng D; Johnston JJ; Teer JK; Stenson PD; Cooper DN; Mullikin JC; Biesecker LG;
Anesthesiology; 2013 Nov; 119(5):1043-53. PubMed ID: 24195946
[TBL] [Abstract][Full Text] [Related]
2. Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families.
Kim JH; Jarvik GP; Browning BL; Rajagopalan R; Gordon AS; Rieder MJ; Robertson PD; Nickerson DA; Fisher NA; Hopkins PM
Anesthesiology; 2013 Nov; 119(5):1054-65. PubMed ID: 24013571
[TBL] [Abstract][Full Text] [Related]
3. Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of
Sadhasivam S; Brandom BW; Henker RA; McAuliffe JJ
Pharmacogenomics; 2019 Sep; 20(14):989-1003. PubMed ID: 31559918
[No Abstract] [Full Text] [Related]
4. Pharmacogenetics and pathophysiology of CACNA1S mutations in malignant hyperthermia.
Beam TA; Loudermilk EF; Kisor DF
Physiol Genomics; 2017 Feb; 49(2):81-87. PubMed ID: 28011884
[TBL] [Abstract][Full Text] [Related]
5. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States.
Brandom BW; Bina S; Wong CA; Wallace T; Visoiu M; Isackson PJ; Vladutiu GD; Sambuughin N; Muldoon SM
Anesth Analg; 2013 May; 116(5):1078-1086. PubMed ID: 23558838
[TBL] [Abstract][Full Text] [Related]
6. Next-generation Sequencing of RYR1 and CACNA1S in Malignant Hyperthermia and Exertional Heat Illness.
Fiszer D; Shaw MA; Fisher NA; Carr IM; Gupta PK; Watkins EJ; Roiz de Sa D; Kim JH; Hopkins PM
Anesthesiology; 2015 May; 122(5):1033-46. PubMed ID: 25658027
[TBL] [Abstract][Full Text] [Related]
7. Genetic epidemiology of malignant hyperthermia in the UK.
Miller DM; Daly C; Aboelsaod EM; Gardner L; Hobson SJ; Riasat K; Shepherd S; Robinson RL; Bilmen JG; Gupta PK; Shaw MA; Hopkins PM
Br J Anaesth; 2018 Oct; 121(4):944-952. PubMed ID: 30236257
[TBL] [Abstract][Full Text] [Related]
8. Comparison of pathogenicity prediction tools on missense variants in RYR1 and CACNA1S associated with malignant hyperthermia.
Schiemann AH; Stowell KM
Br J Anaesth; 2016 Jul; 117(1):124-8. PubMed ID: 27147545
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the entire ryanodine receptor type 1 and alpha 1 subunit of the dihydropyridine receptor (CACNA1S) coding regions for variants associated with malignant hyperthermia in Australian families.
Gillies RL; Bjorksten AR; Du Sart D; Hockey BM
Anaesth Intensive Care; 2015 Mar; 43(2):157-66. PubMed ID: 25735680
[TBL] [Abstract][Full Text] [Related]
10. Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review.
Kraeva N; Sapa A; Dowling JJ; Riazi S
Can J Anaesth; 2017 Jul; 64(7):736-743. PubMed ID: 28326467
[TBL] [Abstract][Full Text] [Related]
11. Novel missense mutations and unexpected multiple changes of RYR1 gene in 75 malignant hyperthermia families.
Tammaro A; Di Martino A; Bracco A; Cozzolino S; Savoia G; Andria B; Cannavo A; Spagnuolo M; Piluso G; Aurino S; Nigro V
Clin Genet; 2011 May; 79(5):438-47. PubMed ID: 20681998
[TBL] [Abstract][Full Text] [Related]
12. Relevance of pathogenicity prediction tools in human RYR1 variants of unknown significance.
Hoppe K; Jurkat-Rott K; Kranepuhl S; Wearing S; Heiderich S; Merlak S; Klingler W
Sci Rep; 2021 Feb; 11(1):3445. PubMed ID: 33564012
[TBL] [Abstract][Full Text] [Related]
13. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
McCarthy TV; Quane KA; Lynch PJ
Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
[TBL] [Abstract][Full Text] [Related]
14. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility.
Monnier N; Krivosic-Horber R; Payen JF; Kozak-Ribbens G; Nivoche Y; Adnet P; Reyford H; Lunardi J
Anesthesiology; 2002 Nov; 97(5):1067-74. PubMed ID: 12411788
[TBL] [Abstract][Full Text] [Related]
15. Exome sequencing: one small step for malignant hyperthermia, one giant step for our specialty--why exome sequencing matters to all of us, not just the experts.
Nagele P
Anesthesiology; 2013 Nov; 119(5):1006-8. PubMed ID: 24195944
[No Abstract] [Full Text] [Related]
16. Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia.
Galli L; Orrico A; Lorenzini S; Censini S; Falciani M; Covacci A; Tegazzin V; Sorrentino V
Hum Mutat; 2006 Aug; 27(8):830. PubMed ID: 16835904
[TBL] [Abstract][Full Text] [Related]
17. RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.
Isackson PJ; Wang J; Zia M; Spurgeon P; Levesque A; Bard J; James S; Nowak N; Lee TK; Vladutiu GD
Pharmacogenomics; 2018 Nov; 19(16):1235-1249. PubMed ID: 30325262
[TBL] [Abstract][Full Text] [Related]
18. RYR1 mutations as a cause of ophthalmoplegia, facial weakness, and malignant hyperthermia.
Shaaban S; Ramos-Platt L; Gilles FH; Chan WM; Andrews C; De Girolami U; Demer J; Engle EC
JAMA Ophthalmol; 2013 Dec; 131(12):1532-40. PubMed ID: 24091937
[TBL] [Abstract][Full Text] [Related]
19. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.
Monnier N; Kozak-Ribbens G; Krivosic-Horber R; Nivoche Y; Qi D; Kraev N; Loke J; Sharma P; Tegazzin V; Figarella-Branger D; Roméro N; Mezin P; Bendahan D; Payen JF; Depret T; Maclennan DH; Lunardi J
Hum Mutat; 2005 Nov; 26(5):413-25. PubMed ID: 16163667
[TBL] [Abstract][Full Text] [Related]
20. Assessing the pathogenicity of RYR1 variants in malignant hyperthermia.
Merritt A; Booms P; Shaw MA; Miller DM; Daly C; Bilmen JG; Stowell KM; Allen PD; Steele DS; Hopkins PM
Br J Anaesth; 2017 Apr; 118(4):533-543. PubMed ID: 28403410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]